Dual disappointments from the challenging field of advanced lung cancer announced Friday highlighted continuing challenges in addressing the disease, still the leading cause of cancer death in the U.S. despite substantial progress. Astrazeneca plc and its biologics arm Medimmune reported that, for people with metastatic non-small-cell lung cancer (NSCLC), neither the anti-PD-L1 antibody Imfinzi (durvalumab) nor a combination of that drug with the anti-CTLA-4 candidate tremelimumab improved overall survival vs. standard-of-care chemotherapy for previously-untreated patients in the phase III Mystic trial. Astrazeneca's partner Hutchison China Meditech Ltd. (Chi-Med) also reported phase III results showing that, despite improving progression-free survival, its small-molecule inhibitor of VEGF receptors, fruquintinib, failed to improve OS for advanced NSCLC patients who had failed two lines of systemic chemotherapy.